Rocket Pharmaceuticals, Inc. Payments to Acquire Short-term Investments
Rocket Pharmaceuticals, Inc. (RCKT) reported Payments to Acquire Short-term Investments of $27.20 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2018-03-07
- Rocket Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2017-06-30 was $14.48M, a 56.45% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2017-03-31 was $12.72M, a 47.34% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2017 was $27.20M, a 77.75% decline from fiscal 2016.
- Rocket Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2016 was $122.28M, a 262.92% increase from fiscal 2015.
- Rocket Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2015 was $33.69M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $0.00 derived: sum of 2 quarters · filed 2018-03-07 | $14.48M derived: sum of 3 quarters · filed 2018-03-07 | $27.20M 10-K · filed 2018-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $14.48M derived: sum of 2 quarters · filed 2017-11-08 | $27.20M 10-Q · filed 2017-11-08 | $80.41M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $14.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $27.20M 10-Q · filed 2017-08-03 | $80.41M derived: sum of 3 quarters · filed 2018-03-07 | $92.07M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | $12.72M 10-Q · filed 2017-05-10 | $65.93M derived: sum of 2 quarters · filed 2018-03-07 | $77.58M derived: sum of 3 quarters · filed 2018-03-07 | $110.84M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-12-31 | $53.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $64.86M derived: sum of 2 quarters · filed 2018-03-07 | $98.12M derived: sum of 3 quarters · filed 2018-03-07 | $122.28M 10-K · filed 2018-03-07 |
| 2016-09-30 | $11.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $44.91M derived: sum of 2 quarters · filed 2017-11-08 | $69.07M 10-Q · filed 2017-11-08 | $73.65M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $33.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $57.41M 10-Q · filed 2017-08-03 | $61.99M derived: sum of 3 quarters · filed 2017-08-03 | |
| 2016-03-31 | $24.16M 10-Q · filed 2017-05-10 | $28.74M derived: sum of 2 quarters · filed 2017-05-10 | ||
| 2015-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $33.69M 10-K · filed 2017-03-16 | ||
| 2015-09-30 | $29.12M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |